BEFORE YOU BEGIN
What to know.
- Start with the exact product and indication rather than the peptide category.
- An approved use does not validate unrelated wellness claims.
- Research, compounding, and approval are separate concepts.
A clearer path through the details.
Use this reading map to jump to the questions covered below.
Ask what has actually been approved
Tesamorelin illustrates why the indication matters: the EGRIFTA SV label describes reducing excess abdominal fat in adults with HIV-related lipodystrophy and states that it is not indicated for weight-loss management.
That narrow example does not support every use marketed as peptide therapy. Ask the service to identify the exact approved medicine, if any, and whether the proposed use matches its labeling.
Sources: EGRIFTA SV (tesamorelin) prescribing information · Resources for information on approved drugs
Use regulatory terms precisely
FDA describes off-label prescribing as a different use of an approved medicine. Compounded preparations are not FDA-approved medicines. A claim that something is 'off label' should therefore be clarified before it is used to explain a compounded or investigational product.
Ask which category applies to the finished product you would receive. Registration, a laboratory report, or a research citation should not be treated as an approval record for that product and purpose.
Sources: Understanding unapproved use of approved drugs (off label) · Compounding and the FDA: questions and answers · Resources for information on approved drugs
Read evidence at the right level
FDA identifies safety uncertainties for several bulk substances considered for compounding, including immunogenicity and insufficient human safety information for some peptide products. The details vary by substance and route; they should not be reduced to a blanket claim that all peptides are safe or all are prohibited.
For any proposed benefit, ask: Was the study in humans? Did it evaluate the same product, route, population, and outcome? How were harms measured? What remains unknown? Those questions help separate a scientific observation from a recommendation for you.
Sources: Bulk drug substances that may present significant safety risks
TAKE TO YOUR APPOINTMENT
Questions to ask.
- What exact finished product and purpose are being proposed?
- Is there an FDA approval record for that product and use?
- Which human study supports the claimed benefit?
- What safety information is missing, and what alternatives exist?
FOLLOW THE EVIDENCE
Sources & further reading
- EGRIFTA SV (tesamorelin) prescribing informationNIH National Library of Medicine — DailyMed · Accessed October 3, 2026
- Resources for information on approved drugsU.S. Food and Drug Administration · Accessed October 3, 2026
- Understanding unapproved use of approved drugs (off label)U.S. Food and Drug Administration · Accessed October 3, 2026
- Compounding and the FDA: questions and answersU.S. Food and Drug Administration · Accessed October 3, 2026
- Bulk drug substances that may present significant safety risksU.S. Food and Drug Administration · Accessed October 3, 2026
EXPLORING CLINICAL CARE?
A separate next step.
Reform is a separate destination for readers exploring clinical care information. This link does not establish that any peptide is available, approved, or appropriate through that service. Ask about the exact product and evidence before considering care.
Explore clinician-guided care information at ReformPrime Health directs interested readers to Reform. This care-service link is separate from our clinical sources. About this relationship.
